Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 3/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674020 | 1.00 | NQO2 (0.53) | NQO2DYRK1APDGFRBPDGFRANSD2 | |
| SCHEMBL22816626 | 0.84 | KDM4E (0.43) | NQO2PDGFRBPDGFRANSD2CASP6 | |
| SCHEMBL14909856 | 0.83 | KDM4E (0.52) | LMNASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL13301167 | 0.81 | PSMD14 (0.59) | DYRK1APDGFRBPDGFRANSD2CASP6 | |
| SCHEMBL1556194 | 0.81 | CYP1A2 (0.52) | NQO2DYRK1APDGFRBPDGFRALMNA | |
| SCHEMBL25248278 | 0.81 | PDGFRB (0.51) | DYRK1APDGFRBPDGFRANSD2CASP6 | |
| SCHEMBL20521768 | 0.80 | NPC1 (0.54) | LMNASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL2943859 | 0.79 | DYRK1A (0.50) | DYRK1APDGFRBPDGFRANSD2CASP6 | |
| SCHEMBL365374 | 0.79 | DYRK1A (0.50) | DYRK1APDGFRBPDGFRALMNASMN1; SMN2 | |
| SCHEMBL27292852 | 0.79 | HSP90AA1 (0.50) | DYRK1APDGFRBPDGFRANSD2CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12503440-B2 | Nitroxoline derivative, preparation method therefor, and use thereof | Jiangsu Yahong Meditech Co. (CN) | 2025-12-23 | — | — | US | disclosed |
| EP-4623914-A1 | USE OF 8-HYDROXYQUINOLINE DERIVATIVE | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| US-12378201-B2 | Histone demethylase inhibitors for treating cancers | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-08-05 | — | — | US | disclosed |
| CN-120035438-A | Use of 8-hydroxyquinoline derivatives | 江苏亚虹医药科技股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20250122203-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| EP-4433485-A1 | ADENOSINE RECEPTOR ANTAGONISTS | Crossignal Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| US-12065444-B2 | Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists | CROSSIGNAL THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240246916-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| CN-118317965-A | Adenosine receptor antagonists | 交信医药研发公司 | 2024-07-09 | — | — | CN | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| CN-102958918-A | Novel nicotinamide derivatives or salts thereof | FUJIFILM CORP | 2013-03-06 | — | — | CN | disclosed |
| WO-2012002577-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | 富士フイルム株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378201-B2 | Histone demethylase inhibitors for treating cancers | KDM4A, KDM1B, KDM4B | NQO2 1334/4885DYRK1A 1162/4885PDGFRB 2891/4885 |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | NQO2 283/4885DYRK1A 2128/4885PDGFRB 176/4885 |
| US-12503440-B2 | Nitroxoline derivative, preparation method therefor, and use thereof | NOS1, NQO1, NOS2 | NQO2 67/4885DYRK1A 4182/4885PDGFRB 4153/4885 |
| US-20240246916-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF | CYP3A7, UGT1A7, UGT2B7 | NQO2 31/4885DYRK1A 4501/4885PDGFRB 3709/4885 |
| US-20250122203-A1 | ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | NQO2 1395/4885DYRK1A 3647/4885PDGFRB 1301/4885 |
| US-12065444-B2 | Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists | ADORA2A, ADORA1, P2RX5 | NQO2 2753/4885DYRK1A 1775/4885PDGFRB 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.